Immune checkpoint inhibitors can stimulate the body’s anti-tumor immune system, but they can also have toxic effects called immune-related adverse events (irAEs). Colitis is a common and serious immune-related adverse event that can cause treatment interruption. As researchers did not observe a strong colitis response in laboratory mice treated with checkpoint inhibitors, Therefore, the understanding of the underlying mechanisms of intestinal immune-related adverse events is often hindered. Recently, an article…
CTLA-4
The Reasons for The Therapeutic Effect of CTLA-4 Inhibitors Being Sluggish
As the “predecessors” in immune checkpoint inhibitors, the development of anti-CTLA-4 monoclonal antibodies in recent years has not been ideal. From the perspective of approved indications, their single-drug treatment uses are few and can only be paired with PD-1/L1 inhibitors. If we look at the failure cases of clinical research, it will be even more heart-wrenching. So the question is, what is blocking the anti-CTLA-4 monoclonal antibody? The research…